Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial

References

• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Bell MD, Lysaker PH, Milstein RM, Beam-Goulet JL. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res 1994; 54: 51–58
   PubMed Web of Science ®Google Scholar
• Borison, RL, Arvanitis, LA, Miller, BG, the US Seroquel Study Group. 1996. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 162: 158–169.
   Google Scholar
• Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002; 16: 219–228
   PubMed Web of Science ®Google Scholar
• Casey DE. “Seroquel” (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996; 5(8)939–957
   Google Scholar
• Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M, the Ziprasidone Study Group. 1999. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology, 20:491–505.
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6)553–64
   PubMed Web of Science ®Google Scholar
• Emsley, R, Rabinowitz, J, Torreman, M; RIS-INT-35 Early Psychosis Global Working Group. 2003. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res, 61(1)47–57.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 1995; 91(Suppl 388)24–30
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Rockville, MD 1976
   Google Scholar
• Hedenmalm K, Hägg S, Ståhl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Safety 2002; 25: 1107–1116
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Murasaki M, Miura S. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. Psychiatry Clin Neurosci 2000; 54(4)467–478
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2)261–276
   PubMed Web of Science ®Google Scholar
• Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week, placebo-controlled trial. Psychopharmacology (Berlin) 1998; 140: 173–184
   PubMed Web of Science ®Google Scholar
• Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841–852
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57(Suppl 11)68–71
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209–1223
   PubMed Web of Science ®Google Scholar
• Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordic J Psychiatry 2001; 55(Suppl 44)5–69
   PubMed Web of Science ®Google Scholar
• Schooler NR. Maintaining symptom control: review of ziprasidone long-term efficacy data. J Clin Psychiatry 2003; 64(Suppl 19)26–32
   PubMedGoogle Scholar
• Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999; 353: 1425–30
   PubMed Web of Science ®Google Scholar
• Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–113
   PubMed Web of Science ®Google Scholar
• Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare?. Psychiatr Q 2002; 73: 297–311
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856–865
   PubMed Web of Science ®Google Scholar